{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:17:02Z","timestamp":1788283022931,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) with the alpha-emitter actinium-225 (\n                      <jats:sup>225<\/jats:sup>\n                      Ac) has shown promising activity in metastatic castration-resistant prostate cancer (mCRPC), but its use is limited by toxicity. A tandem approach combining [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617 and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 (actinium-lutetium) has been developed to mitigate adverse effects and optimize efficacy. Given the scarcity of\n                      <jats:sup>225<\/jats:sup>\n                      Ac and the emergence of resistance, early identification of non-responders is crucial. Circulating tumor DNA (ctDNA), especially tumor fraction (TFx) estimated from ultra-low-pass whole genome sequencing (ULP-WGS) using ichorCNA, may provide a non-invasive biomarker for monitoring treatment response. Blood samples were collected from mCRPC patients treated with actinium-lutetium bimonthly. Cell-free DNA (cfDNA) was extracted and analyzed by ULP-WGS (\u2264\u20097\u2009\u00d7\u2009coverage). TFx was derived using ichorCNA and compared longitudinally with prostate-specific antigen (PSA) and imaging data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patient 1 achieved complete remission with undetectable PSA and TFx after two cycles. Patient 2 showed a strong and sustained therapeutic response; however, after a prolonged treatment hiatus, ctDNA analysis detected genomic progression despite stable PSA levels. Patient 3 initially responded to therapy, but TFx began rising during the third cycle, preceding PSA relapse, indicating early disease progression. Patient 4, classified as a non-responder, showed only transient TFx reduction and experienced rapid disease progression, with increasing PSA and TFx levels already by the second cycle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Longitudinal ctDNA TFx dynamics enable early detection of response and resistance to actinium-lutetium in mCRPC and may complement PSMA imaging to guide timely, personalized treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01388-x","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:17:18Z","timestamp":1770801438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0693-9241","authenticated-orcid":false,"given":"Mariam","family":"Amghar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"\u00d6zg\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Roscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bauder-W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Bene\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bene\u0161ov\u00e1-Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1388_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013.","journal-title":"Eur Urol"},{"key":"1388_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1388_CR3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med"},{"key":"1388_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721\u20138. https:\/\/doi.org\/10.1007\/s00259-019-04612-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1388_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225 Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"key":"1388_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05778-w","author":"IO Lawal","year":"2022","unstructured":"Lawal IO, Morgenstern A, Vorster M, Knoesen O, Mahapane J, Hlongwa KN, et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05778-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1388_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081926","author":"T Langbein","year":"2022","unstructured":"Langbein T, Kulkarni HR, Schuchardt C, Mueller D, Volk GF, Baum RP. Salivary gland toxicity of PSMA-targeted radioligand therapy with (177)Lu-PSMA and combined (225)Ac- and (177)Lu-labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics12081926.","journal-title":"Diagnostics (Basel)"},{"key":"1388_CR8","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.7150\/thno.56211","volume":"11","author":"F Rosar","year":"2021","unstructured":"Rosar F, Hau F, Bartholoma M, Maus S, Stemler T, Linxweiler J, et al. Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617\/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11:4050\u201360. https:\/\/doi.org\/10.7150\/thno.56211.","journal-title":"Theranostics"},{"key":"1388_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2011.11.009","volume":"12","author":"AJ Armstrong","year":"2011","unstructured":"Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2011;12:61. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.009.","journal-title":"Eur Urol"},{"key":"1388_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060906","author":"U Hennrich","year":"2025","unstructured":"Hennrich U, Wagner L, Ta\u015f H, Kovacs L, Bene\u0161ov\u00e1-Sch\u00e4fer M. Revolutionizing prostate cancer detection: the role of approved PSMA-PET imaging agents. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18060906.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1388_CR11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264944","author":"J Cardinale","year":"2023","unstructured":"Cardinale J, Giesel FL, Wensky C, Rathke HG, Haberkorn U, Kratochwil C. PSMA-GCK01: a generator-based 99mTc\/188Re theranostic ligand for the prostate-specific membrane antigen. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.122.264944.","journal-title":"J Nucl Med"},{"key":"1388_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2012.07.003","author":"JW Weidner","year":"2012","unstructured":"Weidner JW, Mashnik SG, John KD, Ballard B, Birnbaum ER, Bitteker LJ, et al. 225Ac and 223Ra production via 800 MeV proton irradiation of natural thorium targets. Appl Radiat Isot. 2012. https:\/\/doi.org\/10.1016\/j.apradiso.2012.07.003.","journal-title":"Appl Radiat Isot"},{"key":"1388_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.apradiso.2004.06.013","volume":"62","author":"C Apostolidis","year":"2005","unstructured":"Apostolidis C, Molinet R, McGinley J, Abbas K, M\u00f6llenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2005;62:383\u20137. https:\/\/doi.org\/10.1016\/j.apradiso.2004.06.013.","journal-title":"Appl Radiat Isot"},{"issue":"729","key":"1388_CR14","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.urolonc.2020.12.002","volume":"39","author":"MJ van der Doelen","year":"2021","unstructured":"van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with (225)Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol. 2021;39(729):e7\u201316. https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.002.","journal-title":"Urol Oncol"},{"key":"1388_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","volume":"126","author":"M Cisneros-Villanueva","year":"2022","unstructured":"Cisneros-Villanueva M, Hidalgo-P\u00e9rez L, Rios-Romero M, Cedro-Tanda A, Ruiz-Villavicencio CA, Page K, et al. Cell-free DNA analysis in current cancer clinical trials: a review. Br J Cancer. 2022;126:391\u2013400. https:\/\/doi.org\/10.1038\/s41416-021-01696-0.","journal-title":"Br J Cancer"},{"key":"1388_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mrrev.2019.05.002","volume":"781","author":"K Cervena","year":"2019","unstructured":"Cervena K, Vodicka P, Vymetalkova V. Diagnostic and prognostic impact of cell-free DNA in human cancers: systematic review. Mutation Research\/Reviews in Mutation Research. 2019;781:100\u201329. https:\/\/doi.org\/10.1016\/j.mrrev.2019.05.002.","journal-title":"Mutation Research\/Reviews in Mutation Research"},{"key":"1388_CR17","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/0008-5472.Can-13-2030","volume":"73","author":"K Pantel","year":"2013","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013;73:6384\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-2030.","journal-title":"Cancer Res"},{"key":"1388_CR18","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00259-025-07280-5","volume":"52","author":"K Kluge","year":"2025","unstructured":"Kluge K, Haberl D, Haug A, Kenner L, Kramer G, Shariat S, et al. Genomic instability is associated with response to [\u00b9\u2077\u2077Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis. Eur J Nucl Med Mol Imaging. 2025;52:4151\u20136. https:\/\/doi.org\/10.1007\/s00259-025-07280-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1388_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122109","author":"AD Choudhury","year":"2018","unstructured":"Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.122109.","journal-title":"JCI Insight"},{"key":"1388_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker M, Goldstein LD, Murray DH, Tao J, Pathmanandavel S, Boulter N, et al. Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617. Eur Urol Open Sci. 2023;57:30\u20136. https:\/\/doi.org\/10.1016\/j.euros.2023.08.007.","journal-title":"Eur Urol Open Sci"},{"issue":"9","key":"1388_CR21","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41416-021-01508-5","volume":"125","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi U, Sansovini M, Severi S, et al. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a phase 2 trial. Br J Cancer. 2021;125(9):1226\u201332. https:\/\/doi.org\/10.1038\/s41416-021-01508-5.","journal-title":"Br J Cancer"},{"key":"1388_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017. https:\/\/doi.org\/10.1038\/s41467-017-00965-y.","journal-title":"Nat Commun"},{"key":"1388_CR23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2967\/jnumed.119.227470","volume":"60","author":"F Bruchertseifer","year":"2019","unstructured":"Bruchertseifer F, Kratochwil C, Rathke H, Haberkorn U, Morgenstern A, Giesel F.;Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617;. J Nucl Med. 2019;60:466.","journal-title":"J Nucl Med"},{"issue":"7","key":"1388_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","volume":"65","author":"H Rathke","year":"2024","unstructured":"Rathke H, Winter E, Bruchertseifer F, R\u00f6hrich M, Giesel FL, Haberkorn U, et al. Deescalated (225)Ac-PSMA-617 versus (177)Lu\/(225)Ac-PSMA-617 cocktail therapy: a single-center retrospective analysis of 233 patients. J Nucl Med. 2024;65(7):1057\u201363. https:\/\/doi.org\/10.2967\/jnumed.123.267206.","journal-title":"J Nucl Med"},{"key":"1388_CR25","doi-asserted-by":"publisher","unstructured":"Yazdanpanah O, Calais J, Chi KN, Bono JSD, Deymann S, El-Haddad G, et al. Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. J Clin Oncol. 2025;43:121. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.121.","DOI":"10.1200\/JCO.2025.43.5_suppl.121"},{"key":"1388_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","volume":"32","author":"A Jayaram","year":"2021","unstructured":"Jayaram A, Wingate A, Wetterskog D, Wheeler G, Sternberg CN, Jones R, et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann Oncol. 2021;32:726\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.196.","journal-title":"Ann Oncol"},{"key":"1388_CR27","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.Ccr-22-2998","volume":"29","author":"SH Tolmeijer","year":"2023","unstructured":"Tolmeijer SH, Boerrigter E, Sumiyoshi T, Kwan EM, Ng SWS, Annala M, et al. Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29:2835\u201344. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2998.","journal-title":"Clin Cancer Res"},{"key":"1388_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.5306\/wjco.v11.i7.450","volume":"11","author":"N Sobhani","year":"2020","unstructured":"Sobhani N, Sirico M, Generali D, Zanconati F, Scaggiante B. Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer. World J Clin Oncol. 2020;11:450\u201363. https:\/\/doi.org\/10.5306\/wjco.v11.i7.450.","journal-title":"World J Clin Oncol"},{"key":"1388_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707945","author":"DWY Tsui","year":"2018","unstructured":"Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, Chandrananda D, et al. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR\u2010targeted therapies in non\u2010small cell lung cancer. EMBO Mol Med. 2018. https:\/\/doi.org\/10.15252\/emmm.201707945.","journal-title":"EMBO Mol Med"},{"key":"1388_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-020-00765-2","author":"Y Chen","year":"2020","unstructured":"Chen Y, Sadasivan SM, She R, Datta I, Taneja K, Chitale D, et al. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival. BMC Med Genomics. 2020. https:\/\/doi.org\/10.1186\/s12920-020-00765-2.","journal-title":"BMC Med Genomics"},{"key":"1388_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092219","author":"V Conteduca","year":"2022","unstructured":"Conteduca V, Casadei C, Scarpi E, Brighi N, Schepisi G, Lolli C, et al. Baseline plasma tumor DNA (ctDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14092219.","journal-title":"Cancers"},{"key":"1388_CR32","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.Ccr-24-1096","volume":"30","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney CJ, Petry R, Xu C, Childress M, He J, Fabrizio D, et al. Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2024;30:4115\u201322. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1096.","journal-title":"Clin Cancer Res"},{"key":"1388_CR33","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2016.0656","author":"R Tourinho-Barbosa","year":"2018","unstructured":"Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol. 2018. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2016.0656.","journal-title":"Int Braz J Urol"},{"key":"1388_CR34","doi-asserted-by":"publisher","DOI":"10.14423\/SMJ.0000000000000266","author":"FH Karzai","year":"2015","unstructured":"Karzai FH, Madan RA, Figg WD. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. South Med J. 2015. https:\/\/doi.org\/10.14423\/SMJ.0000000000000266.","journal-title":"South Med J"},{"key":"1388_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.Cd-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7:1006\u201317. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0261.","journal-title":"Cancer Discov"},{"key":"1388_CR36","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1155\/2021\/1544208","volume":"18","author":"S McGeorge","year":"2021","unstructured":"McGeorge S, Kwok M, Jiang A, Emmett L, Pattison DA, Thomas PA, et al. Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. Adv Urol. 2021;18:2021. https:\/\/doi.org\/10.1155\/2021\/1544208.","journal-title":"Adv Urol"},{"key":"1388_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00259-022-05961-z","volume":"50","author":"I Alberts","year":"2023","unstructured":"Alberts I, Schepers R, Zeimpekis K, Sari H, Rominger A, Afshar-Oromieh A. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET\/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50:951\u20136. https:\/\/doi.org\/10.1007\/s00259-022-05961-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1388_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.004","author":"O Amato","year":"2023","unstructured":"Amato O, Aftimos P, Ignatiadis M. Liquid biopsy accelerates precision medicine. Ann Oncol. 2023. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.004.","journal-title":"Ann Oncol"},{"key":"1388_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100156","author":"EF Saldanha","year":"2024","unstructured":"Saldanha EF, Nicolo E, Venetis K, Miguel-Perez D, Ortega-Franco A, Dipasquale A, et al. The role of liquid biopsy as a catalyst for sustained progress in precision oncology \u2013 perspective of the young committee of the international society of liquid biopsy. The Journal of Liquid Biopsy. 2024. https:\/\/doi.org\/10.1016\/j.jlb.2024.100156.","journal-title":"The Journal of Liquid Biopsy"},{"key":"1388_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-021-00939-5","author":"K Watanabe","year":"2021","unstructured":"Watanabe K, Nakamura Y, Low S-K, Watanabe K, Nakamura Y, Low S-K. Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021. https:\/\/doi.org\/10.1038\/s10038-021-00939-5.","journal-title":"J Hum Genet"},{"key":"1388_CR41","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"S-J Dawson","year":"2013","unstructured":"Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199\u2013209. https:\/\/doi.org\/10.1056\/NEJMoa1213261.","journal-title":"N Engl J Med"},{"key":"1388_CR42","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548\u201354. https:\/\/doi.org\/10.1038\/nm.3519.","journal-title":"Nat Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01388-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:05:01Z","timestamp":1781633101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01388-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval (S-882\/2020) from the Ethics Committee of the Medical Faculty at Heidelberg University. This project is a non-interventional, exploratory investigation focusing on therapy resistance in patients treated with [\n                      225\n                      Ac]Ac-\/[\n                      177\n                      Lu]Lu-PSMA-617. The study complies with national regulations, the Declaration of Helsinki, and Good Clinical Practice (GCP) guidelines. Furthermore, in accordance with Paragraph 13(2b) of the German Pharmaceuticals Law, the therapy was administered as a salvage treatment for patients with mCRPC who had progressive disease and were either resistant to or ineligible for approved therapeutic options.\u00a0Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication of anonymized data was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A patent application for PSMA-617 has been filed by the German Cancer Research Center (DKFZ) and the University Clinic Heidelberg (UKHD). Ulrike Bauder-W\u00fcst, Clemens Kratochwil, and Martina Bene\u0161ov\u00e1-Sch\u00e4fer are co-inventors of this patent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}